![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Proceeds will support the clinical development of MT-101, Myeloid’s lead cell therapy program in Phase 1/2 for T cell lymphoma, and will accelerate the development of MT-302, a first-in-class TROP2-FcA mRNA-LNP product, into a Phase 1/2 for TROP2-expressing tumors.
Lead Product(s): MT-101,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: MT-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Hatteras Investment Partners
Deal Size: $73.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 18, 2023
Details:
Through this agreement, Myeloid de-risks the development of its candidates by leveraging Acuitas’ science and proven regulatory, to rapidly translate Myeloid’s innovation to patients. The MT-301 and MT-302 programs will utilize Acuitas’ LNP deliver technology.
Lead Product(s): MT-301
Therapeutic Area: Oncology Product Name: MT-301
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Acuitas
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 19, 2022
Details:
Myeloid dosed MT-101 in a patient with refractory PTCL within 18 months, illustrating the potential of mRNA therapies to help patients sooner and to accelerate Myeloid's portfolio.
Lead Product(s): MT-101,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: MT-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2022
Details:
Myeloid has advanced its lead development candidates including MT-101 through preclinical studies, implemented its manufacturing platform and plans to dose patients in the first half of this year.
Lead Product(s): MT-101
Therapeutic Area: Oncology Product Name: MT-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Newpath Partners
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 06, 2021